Novartis has reached an agreement to buy Regulus Therapeutics and its experimental therapy for autosomal dominant polycystic kidney disease (ADPKD) for $800 million upfront in a deal that could have a ...
Veronica Beagle is the managing editor for Education at Forbes Advisor. She completed her master’s in English at the University of Hawai‘i at Mānoa. Before coming to Forbes Advisor she worked on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results